Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Advanced Solid Tumors 173Advanced Solid Tumor 150Solid Tumor 129Mesothelioma 88Mesothelioma, Malignant 82Solid Tumors 79Hematopoietic and Lymphatic System Neoplasm 47Solid Tumor, Adult 35Carcinoma, Non-Small-Cell Lung 32Retinoblastoma 29Ovarian Neoplasms 26Melanoma 24Colorectal Neoplasms 22Pancreatic Neoplasms 21Stomach Neoplasms 20Sarcoma 20Lung Neoplasms 19Carcinoma, Renal Cell 18Uterine Cervical Neoplasms 16Esophageal Neoplasms 16Neoplasms 15Malignant Solid Neoplasm 15Neoplasm Metastasis 14Hematopoietic and Lymphoid System Neoplasm 14Advanced or Metastatic Solid Tumors 14Triple Negative Breast Neoplasms 13Solid Tumor Malignancies 13Small Cell Lung Carcinoma 13Advanced Malignant Solid Tumor 13Urinary Bladder Neoplasms 12

Interventions

atezolizumab 1Tiragolumab 1Specimen Handling 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Rare Malignant Solid Neoplasm × Other solid neoplasm × 1 year × Clear all
NCT05715281 2025-11-25

Testing the Combination of Anti-cancer Drugs Atezolizumab and Tiragolumab in People With Advanced Stage Rare Cancers, RARE3 Trial

National Cancer Institute (NCI)

Phase 2 Active not recruiting
12 enrolled
Other solid neoplasm

Advanced Rare Malignant Solid Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡